Akero Therapeutics (AKRO) has hired an investment bank and is exploring a potential sale after being approached by a strategic buyer about a takeover, according to Street Insider, citing a source.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target
- Akero Therapeutics price target lowered to $78 from $80 at Citi
- Akero Therapeutics Advances in MASH Treatment Research
- Akero Therapeutics price target lowered to $84 from $90 at Morgan Stanley
- Akero Therapeutics: Strong Financial Health and Promising Clinical Data Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue